Patients were admitted to a clinical research center for continuous observation during the infusion period. The first infusion of AAT (Aralast NP™, Baxter AG) was given at a rate of 0.08 mL/kg/min for the entire infusion. For the second infusion the starting rate was 0.08 mL/kg/min, which was increased to 0.14 mL/kg/min, and then up to 0.2 mL/kg/min if tolerated.
Aralast np
Manufactured by Baxter
Sourced in United States
Aralast NP is a laboratory product manufactured by Baxter, which is a recombinant alpha-1 proteinase inhibitor. It is intended for use in research and development applications.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using aralast np
1
Intravenous Infusion of AAT Therapy
2
Reagents and Antibodies Used in Research
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Reagents, including LPS and rabbit anti-JMJD6 (PSR) antibody, were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Aralast NP and Prolastin C was from Baxter International Inc. (Chicago, IL, USA) and Grifols (LA, CA, USA), respectively. Phorbol 12-myristate 13-acetate (PMA), rabbit anti-MAR antibody, rabbit anti-iNOS antibody, rabbit polyclonal anti-GAPDH, mouse monoclonal anti-vinculin were from Abcam (Cambridge, MA, USA), rabbit anti-SRB-2 antibody was from Santa Cruz Biotechnology (Dallas, TX, USA), mouse anti-human CD3 was from BD Biosciences (Franklin Lakes, NJ, USA), recombinant rat IL-4 was from ProSpec-Tany TechnoGene (Ness-Ziona, Israel), and TNF-α Protease Inhibitor-1 (TAPI-1) was from ESD Millipore (Billerica, MA, USA).
3
SP16 and LRP1 Modulation in Cerebral Ischemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We randomly assigned 5 to 8 mice to the different groups of treatment given as a single intraperitoneal administration immediately after reperfusion: SP16 10 μg, SP16 100 μg, SP34 100 μg, matching volume of vehicle to SP16, LRP1 blocking antibody clone 5A6 (Molecular Innovations) 3 mg/kg, LRP1 blocking antibody (3 mg/kg) and SP16 100 μg, plasma-derived AAT 60 mg/kg (Aralast NP, Baxter, Deerfield, Illinois), and LRP1 antibody and AAT.
To simulate a clinical scenario in which treatment may not occur immediately at reperfusion, we added another group of 5 to 8 mice in which SP16 was administered intraperitoneally with a delay of 30 min after reperfusion. Each group included 5 to 8 mice per experiment.
In a final set of experiments we treated 4 to 6 mice with SP16 administered a single dose of 3, 10, 100, or 500 μg given subcutaneously after reperfusion, to test the clinical value of this delivery route.
To simulate a clinical scenario in which treatment may not occur immediately at reperfusion, we added another group of 5 to 8 mice in which SP16 was administered intraperitoneally with a delay of 30 min after reperfusion. Each group included 5 to 8 mice per experiment.
In a final set of experiments we treated 4 to 6 mice with SP16 administered a single dose of 3, 10, 100, or 500 μg given subcutaneously after reperfusion, to test the clinical value of this delivery route.
4
Evaluation of Alpha-1 Antitrypsin in Hepatocyte Transplantation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Alpha-1 antitrypsin was provided by Professor Maria Koulmanda (Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA). Alpha-1 antitrypsin (Aralast NP, Baxter, US Inc.) is prepared from large pools of human plasma and is treated with a solvent detergent to inactivate enveloped viral agents such as HIV, HBV and HCV. The half-life of AAT is reported to be between 3 and 5 days [23 (link)]. Aralast NP was supplied as a lyophilised powder and was freshly reconstituted in sterile water for injection and used within 3 h. The recommended human dosage is 60–120 mg/kg, which based on an average weight of 70 kg and average blood volume of 5 l is equivalent to 0.84–1.7 mg/ml of blood. Initial concentrations of 2 mg/ml and 4 mg/ml AAT were tested in the Chandler loop and compared to the controls of blood only, hepatocytes only and hepatocytes and 1 U/ml heparin (see supplementary material ). For rat hepatocyte transplantations, 120 mg/kg AAT was used.
5
Immunosuppression and Anti-inflammatory Agents
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!